Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELVIQ cardiovascular outcomes and diabetes prevention study in overweight and obese adults at cardiovascular risk
2013-000324-34Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and prediabetes comparing BELVIQ with Placebo (2 arms). Primary endpoint: Time to first major adverse cardiovascular event. Started Jul 2014; status: completed.
02
Drugs
lorcaserin
03
Conditions
obesityOverweightprediabetes
Beyond the preview
Go deeper on 2013-000324-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000324-34.